Liu, Ping-Yen
Su, Cheng-Huang
Kuo, Feng-Yu
Lee, Wen-Lieng
Wang, Yi-Chih
Lin, Wei-Shiang
Chu, Pao-Hsien
Lu, Tse-Min
Lo, Ping-Han
Lee, Cheng-Han
Lan, Wei-Ren
Huang, Chien-Lung
Tsukiyama, Shuji
Yang, Wei-Chen
Cheng, Li-Chung
Rafael, Virginia
Nikolajsen, Christian
Yin, Wei-Hsian
Clinical trials referenced in this document:
Documents that mention this clinical trial
Prasugrel switching from clopidogrel after percutaneous coronary intervention for acute coronary syndrome in Taiwanese patients: an analysis of safety and efficacy
https://doi.org/10.1007/s12928-021-00771-w
Funding for this research was provided by:
Daiichi-Sankyo Co., Ltd.
Article History
Received: 30 October 2020
Accepted: 20 March 2021
First Online: 4 April 2021
Change Date: 22 May 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s12928-021-00779-2
Declarations
:
: Shuji Tsukiyama, Wei-Chen Yang, and Li-Chung Cheng are Daiichi-Sankyo employees. Virginia Rafael and Christian Nikolajsen are Linical employees and participated in a project sponsored by Daiichi Sankyo. Wen-Lieng Lee was a chair of a meeting sponsored by Daiichi Sankyo.
: The Switch Study protocol was approved by the institutional ethics committees of each study site prior to study initiation. This study was conducted in compliance with the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use Harmonized Tripartite Guideline for Good Clinical Practice, the local laws and regulations of Taiwan, and the Declaration of Helsinki. The study was sponsored by Daiichi Sankyo Co., Ltd., and registered onExternalRef removed(Registration Number: NCT03672097).
: Written informed consent for trial participation was obtained from all study subjects before trial screening. A separate informed consent for <i>CYP2C19</i> genotyping was provided at trial screening, and only those who provided the corresponding written informed consent were subjected to such a test.